GlassScriptPhysician profile
Michael W Cannon
NPI 1982666236
$9,352.91
in general payments reported to CMS, 2019-2025
51 companies · $589 in 2025
The $589 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,290 · 2020: $2,734 · 2021: $1,097 · 2022: $172 · 2023: $281 · 2024: $190 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $950 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $950.14 |
| Education | $109.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dova Pharmaceuticals | $992.76 | 2020 | |
| Abbvie INC. | $954.97 | 2019-2023 | Venclexta |
| Rigel Pharmaceuticals, INC. | $876.82 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $668.77 | 2019-2025 | Enhertu, Imfinzi |
| Novartis Pharmaceuticals Corporation | $608.00 | 2019-2025 | |
| Pfizer INC. | $581.07 | 2019-2025 | |
| Genentech USA, INC. | $513.47 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $432.69 | 2019-2021 | |
| Janssen Biotech, INC. | $425.39 | 2019-2025 | Erleada, Rybrevant |
| Merck Sharp & Dohme LLC | $359.49 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Amgen INC. | $324.12 | 2019-2021 | |
| Lilly USA, LLC | $256.95 | 2019-2025 | Verzenio, Jaypirca |
| Seagen INC. | $222.82 | 2019-2021 | |
| Celgene Corporation | $207.64 | 2019-2025 | Pomalyst, Reblozyl |
| Eisai INC. | $199.89 | 2019-2025 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.